Gemini Therapeutics (NASDAQ:GMTX) Hits New 1-Year High at $32.55

Gemini Therapeutics, Inc. (NASDAQ:GMTX) shares reached a new 52-week high on Monday . The company traded as high as $32.55 and last traded at $30.52, with a volume of 387330 shares traded. The stock had previously closed at $31.83.

Gemini Therapeutics Stock Down 1.9 %

The firm has a market cap of $1.30 billion, a price-to-earnings ratio of -30.52 and a beta of -0.12. The stock has a 50 day moving average of $57.56 and a 200 day moving average of $55.49.

Institutional Trading of Gemini Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC purchased a new stake in Gemini Therapeutics in the 2nd quarter valued at $35,000. Goldman Sachs Group Inc. raised its holdings in shares of Gemini Therapeutics by 80.1% during the 2nd quarter. Goldman Sachs Group Inc. now owns 36,635 shares of the company’s stock valued at $62,000 after buying an additional 16,297 shares in the last quarter. UBS Group AG purchased a new position in shares of Gemini Therapeutics during the 2nd quarter valued at about $234,000. Bank of Montreal Can purchased a new position in shares of Gemini Therapeutics during the 2nd quarter valued at about $276,000. Finally, Renaissance Technologies LLC increased its stake in Gemini Therapeutics by 2,850.4% in the 1st quarter. Renaissance Technologies LLC now owns 351,100 shares of the company’s stock worth $488,000 after purchasing an additional 339,200 shares during the period. 75.42% of the stock is currently owned by institutional investors.

About Gemini Therapeutics

Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.